Vivli

RRID:SCR_018080
Type: Tool

Proper Citation

Vivli (RRID:SCR_018080)

Resource Information

URL: https://vivli.org/

Proper Citation: Vivli (RRID:SCR_018080)

Description: Independent, non-profit organization that has developed global data-sharing and analytics platform to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through creation and implementation of sustainable global data-sharing enterprise. Our focus is on sharing individual participant-level data from completed clinical trials. Users can search listed studies, request data sets from data contributors, aggregate data, or share data of their own. Vivli (Center for Clinical Research Data) is launching a portal to share participant-level data from COVID trials.

Resource Type: storage service resource, service resource, data or information resource, data repository, portal, organization portal

Keywords: Global data sharing, clinical research data, data, sharing, analytical platform, clinical trial, COVID-19-related trials

Related Condition: COVID-19

Funding Agency: Doris Duke Charitable Foundation, Leona M. and Harry B. Helmsley Charitable Trust, Lyda Hill Philanthropies, Phrma

Availability: Restricted

Resource Name: Vivli

Resource ID: SCR_018080
Ratings and Alerts

No rating or validation information has been found for Vivli.

No alerts have been found for Vivli.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 577 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID.


Taylor PC, et al. (2023) Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatology and therapy, 10(2), 463.

Foster WJ, et al. (2023) A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution. Drugs in R&D, 23(1), 43.

Lynde C, et al. (2023) Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. Advances in therapy, 40(3), 869.


de Azambuja E, et al. (2023) Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), 100772.